ENX-104
Antibiotic compound
| ENX-104 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
ENX-104 is a novel antibiotic compound that belongs to the class of beta-lactam antibiotics. It is currently under investigation for its potential use in treating infections caused by Gram-negative bacteria.
Mechanism of Action[edit | edit source]
ENX-104 functions by inhibiting bacterial cell wall synthesis. Like other beta-lactam antibiotics, it targets the penicillin-binding proteins (PBPs) that are essential for the cross-linking of the peptidoglycan layer in bacterial cell walls. This inhibition leads to cell lysis and death of the bacteria.
Spectrum of Activity[edit | edit source]
ENX-104 has shown activity against a broad range of Gram-negative bacteria, including strains that are resistant to other antibiotics. It is particularly effective against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
Development and Clinical Trials[edit | edit source]
ENX-104 is currently in the early stages of clinical development. Preclinical studies have demonstrated its efficacy in vitro and in animal models. Clinical trials are being conducted to evaluate its safety, tolerability, and efficacy in humans.
Potential Applications[edit | edit source]
The development of ENX-104 is particularly significant in the context of increasing antibiotic resistance. It offers a potential new treatment option for infections that are difficult to treat with existing antibiotics. ENX-104 could be used in hospital settings for severe infections, especially in patients with compromised immune systems.
Challenges and Considerations[edit | edit source]
While ENX-104 shows promise, there are challenges in its development. These include ensuring its stability, optimizing its pharmacokinetic properties, and minimizing potential side effects. Additionally, the emergence of resistance to ENX-104 itself is a concern that needs to be addressed through careful monitoring and stewardship.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
